Company record · updated August 5, 2026
Aerovate Therapeutics Inc: 2 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs October 31, 2024 to October 31, 2024.
2observations
2source filings
2verified rows
2024-10-31most recent as-of date
Source rails for this company: N-PORT fund mark (2).
Reported by 2 filers: Fidelity Small Cap Growth Fund, Fidelity Small Cap Growth K6 Fund.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-10-31 | price per share | 4.949 USD | Fidelity Small Cap Growth K6 Fund | VERIFIED | valUSD 1145949.17 / balance 231554.0 [unspecified] | 000175272424297793 |
| 2024-10-31 | price per share | 4.9489 USD | Fidelity Small Cap Growth Fund | VERIFIED | valUSD 2732414.27 / balance 552120.0 [unspecified] | 000175272424297811 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.